Minoryx Therapeutics
Business Services · Spain · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Ernest Lluch TCM3 32, Mataro, Catalonia,...Phone Number
+34 935441466Website
www.minoryx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Minoryx Therapeutics
Minoryx is a clinical stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company's lead program, leriglitazone (MIN-102), a novel, selective PPAR agonist, is currently being evaluated in Xlinked Adrenoleukodystrophy (X-ALD) and Friedreich's ataxia. The company is backed by a syndicate of experienced investors, which includes Caixa Capital Risc, Roche Venture Fund, Ysios Capital, Kurma Partners, Fund+, Chiesi Ventures, S.R.I.W, Idinvest, SFPI-FPIM, HealthEquity and Sambrinvest, and has support from a network of other organizations.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Minoryx Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Minoryx Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Minoryx Therapeutics
Earning: See what the market has to say on Minoryx Therapeutics recently announced quarterly report
Check if Minoryx Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Minoryx Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Minoryx Therapeutics had a recent Job posting/layoffs
Check out if Minoryx Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Minoryx Therapeutics has new funding data
Recommended Actions
Find VP level buyers at Minoryx Therapeutics
Find 3 more new buyers
Company Profile Activity
Activity Insights
Minoryx Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Minoryx Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Minoryx Therapeutics.
Minoryx Therapeutics financials insights
Gather financial insights about Minoryx Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Unspecified
$1.9M
2015
Private Equity
$1.8M
Series A
$22.1M
2022
Series C
$55M
Minoryx Therapeutics Tech Stack
A closer look at the technologies used by Minoryx Therapeutics
See more technologies
Minoryx Therapeutics News & Media
Rare Disease Day 2024 - Call for greater awareness of X-linked adrenoleukodystrophy and cerebral adrenoleukodystrophy - special film launched
BARCELONA, Spain and DÜSSELDORF, Germany, Feb. 29, 2024 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, and Minoryx Therapeutics, a late stage biotech company focused...Rare Disease Day 2024 - Call for greater awareness of X-linked adrenoleukodystrophy and cerebral adrenoleukodystrophy - special film launched
BARCELONA, Spain and DÜSSELDORF, Germany, Feb. 29, 2024 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, and Minoryx Therapeutics, a late stage biotech company focused...Minoryx Therapeutics Raises 51M for the commercialization of CNS drug - Born2Invest
Minoryx Therapeutics, based in Mataró (Barcelona), will also finance the activities necessary to be able to proceed with the approval of leriglitazone in the United States for the same indication. Minoryx Therapeutics is currently in discussions with the Food and Drug Administration (FDA) to define the steps required for approval in the United States.
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Minoryx Therapeutics
Sign Up For FreeTo access detailed company insights
Minoryx is a clinical stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company's lead program, leriglitazone (MIN-102), a novel, selective PPAR agonist, is currently being evaluated in Xlinked Adrenoleukodystrophy (X-ALD) and Friedreich's ataxia. The company is backed by... Read More
